
FDA Fast Tracks BioNTech/DualityBio’s Cancer Drug Candidate
FDA Grants Fast Track Designation to BioNTech and DualityBio for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305 BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food…













